← All trials
NCT05662228
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 31, 2023
- Primary completion
- Jul 31, 2027
- Completion date
- Dec 31, 2027
- First posted
- Dec 22, 2022
- Last posted
- Dec 22, 2022
- Enrollment
- 66
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of Colorado, DenverLead sponsor
- University of ColoradoOverall official - principal investigator
- Children's Hospital Los AngelesCollaborator
- Children's Hospital Los AngelesOverall official - principal investigator
- Children's Hospital Los AngelesOfficial
- University of ColoradoOfficial
- Linda Crnic Institute for Down SyndromeOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.